It will compete with Eisai and Biogen's Leqembi, which the FDA approved last year ... Go deeper: Where the future of Alzheimer's drugs is heading Get more health news in your inbox with Axios ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

A whopping 92% agree that Medicare should cover FDA-approved Alzheimer’s drugs for all patients, just as it does for other ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease ... drugs, but potentially life-threatening. It could also face a strong challenge if Eisai and Biogen get approval ...

The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi ... The analysis was based on deaths reported in the FDA Adverse Event Reporting System (FAERS), which states on its ...

(RTTNews) - CervoMed, Inc. (CRVO) announced Wednesday that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

This is unnecessary pain and suffering that could be avoided if we were simply allowed to keep patients on the FDA-approved medication that was appropriate in the first place. Alzheimer’s ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...